scholarly journals β3 Integrin–EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells

2011 ◽  
Vol 22 (22) ◽  
pp. 4288-4301 ◽  
Author(s):  
Nikolas Balanis ◽  
Masaaki Yoshigi ◽  
Michael K. Wendt ◽  
William P. Schiemann ◽  
Cathleen R. Carlin

Active RhoA localizes to plasma membrane, where it stimulates formation of focal adhesions and stress fibers. RhoA activity is inhibited by p190RhoGAP following integrin-mediated cell attachment to allow sampling of new adhesive environments. p190RhoGAP is itself activated by Src-dependent tyrosine phosphorylation, which facilitates complex formation with p120RasGAP. This complex then translocates to the cell surface, where p190RhoGAP down-regulates RhoA. Here we demonstrate that the epidermal growth factor receptor (EGFR) cooperates with β3 integrin to regulate p190RhoGAP activity in mouse mammary gland epithelial cells. Adhesion to fibronectin stimulates tyrosine phosphorylation of the EGFR in the absence of receptor ligands. Use of a dominant inhibitory EGFR mutant demonstrates that fibronectin-activated EGFR recruits p120RasGAP to the cell periphery. Expression of an inactive β3 integrin subunit abolishes p190RhoGAP tyrosine phosphorylation, demonstrating a mechanistic link between β3 integrin–activated Src and EGFR regulation of the RhoA inhibitor. The β3 integrin/EGFR pathway also has a positive role in formation of filopodia. Together our data suggest that EGFR constitutes an important intrinsic migratory cue since fibronectin is a key component of the microenvironment in normal mammary gland development and breast cancer. Our data also suggest that EGFR expressed at high levels has a role in eliciting cell shape changes associated with epithelial-to-mesenchymal transition.

2003 ◽  
Vol 278 (15) ◽  
pp. 13561-13569 ◽  
Author(s):  
Masahiro Zako ◽  
Jianying Dong ◽  
Olga Goldberger ◽  
Merton Bernfield ◽  
John T. Gallagher ◽  
...  

2010 ◽  
Vol 285 (17) ◽  
pp. 13092-13106 ◽  
Author(s):  
Stefano J. Mandriota ◽  
Raphaële Buser ◽  
Laurence Lesne ◽  
Christelle Stouder ◽  
Vincent Favaudon ◽  
...  

2010 ◽  
Vol 22 (9) ◽  
pp. 83
Author(s):  
X. Sun ◽  
S. A. Robertson ◽  
W. V. Ingman

Development of the mammary gland involves complex interactions between epithelial and stromal cells under the influence of hormones and cytokines. Transforming growth factor beta 1 (TGFB1) is a multi-functional cytokine that we have reported to be essential for normal mammary gland development. TGFB1 is produced and secreted as part of a latent complex, and requires activation at the site of action to have biological effects. In situ hybridisation studies have shown mRNA encoding Tgfb1 is mainly expressed by mammary epithelium; however, the expression pattern of active TGFB1 in the mammary gland during different developmental stages is still unclear. Mammary gland tissue was collected from mice at puberty (5 weeks old), adult diestrus and late pregnancy (day 18 pc). Frozen sections were stained with antibody specifically reactive with active TGFB1 protein (not latent TGFB1 or other TGFB isoforms) for immunofluorescent analysis. Qualitative assessment of the staining revealed different patterns of active TGFB1 localisation depending on developmental stage. The strongest expression of active TGFB1 was observed in the mammary gland at diestrus compared to puberty and pregnancy. At diestrus, active TGFB1 was located around the surface of mammary epithelial cells. The staining was heterogeneous, with distinct zones of active TGFB1 accumulated around some but not all epithelial cells. During puberty, active TGFB1 was observed only within the lumen of the ducts. During late pregnancy, TGFB1 was homogenously distributed within the alveolar epithelium. The different patterns of active TGFB1 observed during puberty, diestrus and pregnancy suggest that TGFB1 has different roles in the mammary gland dependent on developmental stage.


2019 ◽  
Vol 116 (23) ◽  
pp. 11437-11443 ◽  
Author(s):  
David Chi ◽  
Hari Singhal ◽  
Lewyn Li ◽  
Tengfei Xiao ◽  
Weihan Liu ◽  
...  

Limited knowledge of the changes in estrogen receptor (ER) signaling during the transformation of the normal mammary gland to breast cancer hinders the development of effective prevention and treatment strategies. Differences in estrogen signaling between normal human primary breast epithelial cells and primary breast tumors obtained immediately following surgical excision were explored. Transcriptional profiling of normal ER+ mature luminal mammary epithelial cells and ER+ breast tumors revealed significant difference in the response to estrogen stimulation. Consistent with these differences in gene expression, the normal and tumor ER cistromes were distinct and sufficient to segregate normal breast tissues from breast tumors. The selective enrichment of the DNA binding motif GRHL2 in the breast cancer-specific ER cistrome suggests that it may play a role in the differential function of ER in breast cancer. Depletion of GRHL2 resulted in altered ER binding and differential transcriptional responses to estrogen stimulation. Furthermore, GRHL2 was demonstrated to be essential for estrogen-stimulated proliferation of ER+ breast cancer cells. DLC1 was also identified as an estrogen-induced tumor suppressor in the normal mammary gland with decreased expression in breast cancer. In clinical cohorts, loss of DLC1 and gain of GRHL2 expression are associated with ER+ breast cancer and are independently predictive for worse survival. This study suggests that normal ER signaling is lost and tumor-specific ER signaling is gained during breast tumorigenesis. Unraveling these changes in ER signaling during breast cancer progression should aid the development of more effective prevention strategies and targeted therapeutics.


Sign in / Sign up

Export Citation Format

Share Document